title: Significance of ACE genotypes and medical treatments in childhood focal glomerulosclerosis.
abstract: BACKGROUND
  There is little information on the significance of angiotensin-converting enzyme (ACE) genotypes and medical treatments in children with primary focal segmental glomerulosclerosis (FSGS).
  
  
  METHODS
  A multicenter retrospective study was performed on the role of ACE genotypes and medical treatments in 43 Japanese children with FSGS (20 males and 23 females), including 17 children who progressed to end-stage renal failure during the mean observation period of 6.9 +/- (SD) 5.0 years.
  
  
  RESULTS
  The incidence of the D allele of the ACE gene was higher in the whole group of 43 children with FSGS and in a subgroup of 28 steroid-resistant FSGS children (p < 0.05) than in the 130 children of the healthy control group (0.48, 0.48, and 0.33, respectively). ACE genotypes did not affect renal survival in the whole FSGS group nor in the steroid-resistant subgroup. Among the 28 steroid-resistant children, treatment with ciclosporin was effective in delaying the development of end-stage renal failure (p = 0.044), independently of other treatment regimens.
  
  
  CONCLUSIONS
  The present study of Japanese children with FSGS showed that the D allele of the ACE gene is associated with the development of FSGS, but not associated with the progression of FSGS which was greatly ameliorated with ciclosporin, irrespective of ACE genotypes.
authors.affiliation: Department of Pediatrics, Fukui Medical University, Fukui, Japan.
authors.forename: C
authors.initials: C
authors.lastname: Hori
authors.forename: M
authors.initials: M
authors.lastname: Hiraoka
authors.forename: N
authors.initials: N
authors.lastname: Yoshikawa
authors.forename: K
authors.initials: K
authors.lastname: Tsuzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshida
authors.forename: K
authors.initials: K
authors.lastname: Yoshioka
authors.forename: K
authors.initials: K
authors.lastname: Fujisawa
authors.forename: H
authors.initials: H
authors.lastname: Tsukahara
authors.forename: Y
authors.initials: Y
authors.lastname: Ohshima
authors.forename: M
authors.initials: M
authors.lastname: Mayumi
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D002648:Child; D018450:Disease Progression; D004351:Drug Resistance; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000209:etiology; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011239:Prednisolone / Q000627:therapeutic use; D011507:Proteinuria / Q000209:etiology; D012044:Regression Analysis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D001552:Benzazepines; D004656:Enalapril; D002216:Captopril; D011239:Prednisolone; D007703:Peptidyl-Dipeptidase A; C044946:benazepril